The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease

[1]  M. Citron.  Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. , 2004, Trends in pharmacological sciences.

[2]  B. Wolozin,et al.  Cholesterol and the Biology of Alzheimer's Disease , 2004, Neuron.

[3]  R. Vassar.  BACE1: the beta-secretase enzyme in Alzheimer's disease. , 2004, Journal of molecular neuroscience : MN.

[4]  Heikki Tanila,et al.  Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice , 2003, Neurobiology of Disease.

[5]  K. Morgan,et al.  Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. , 2003, The international journal of biochemistry & cell biology.

[6]  Christian Haass,et al.  Games Played by Rogue Proteins in Prion Disorders and Alzheimer's Disease , 2003, Science.

[7]  J. Poirier,et al.  The cholesterol-lowering drug Probucol increases apolipoprotein e production in the hippocampus of aged rats: implications for Alzheimer’s disease , 2003, Neuroscience.

[8]  J. Shioi,et al.  A CBP Binding Transcriptional Repressor Produced by the PS1/ϵ-Cleavage of N-Cadherin Is Inhibited by PS1 FAD Mutations , 2003, Cell.

[9]  J. H. Boo,et al.  Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice , 2003, Neurobiology of Aging.

[10]  M. Wolfe,et al.  Intramembrane proteolysis by presenilin and presenilin-like proteases , 2003, Journal of Cell Science.

[11]  B. Strooper,et al.  Aph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex , 2003, Neuron.

[12]  Rudolph E. Tanzi,et al.  Alzheimer's disease: the cholesterol connection , 2003, Nature Neuroscience.

[13]  P. Shah.  Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis. , 2003, Reviews in cardiovascular medicine.

[14]  Doo Yeon Kim,et al.  Nectin-1α, an Immunoglobulin-like Receptor Involved in the Formation of Synapses, Is a Substrate for Presenilin/γ-Secretase-like Cleavage* , 2002, The Journal of Biological Chemistry.

[15]  K. Duff,et al.  Cholesterol in Alzheimer's Disease and Tauopathy , 2002, Annals of the New York Academy of Sciences.

[16]  M. Citron,et al.  Alzheimer's disease: treatments in discovery and development , 2002, Nature Neuroscience.

[17]  Jae-Young Koh,et al.  Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Vicki Olm,et al.  Statin therapy for Alzheimer's disease: will it work? , 2002, Journal of molecular neuroscience : MN.

[19]  C. Chang,et al.  Catalysis of ACAT may be completed within the plane of the membrane: a working hypothesis. , 2001, Journal of lipid research.

[20]  M. Mallory,et al.  Early formation of mature amyloid‐β protein deposits in a mutant APP transgenic model depends on levels of Aβ1–42 , 2001, Journal of neuroscience research.

[21]  T. Hartmann.  Cholesterol, Aβ and Alzheimer's disease , 2001, Trends in Neurosciences.

[22]  T. Hartmann.  Cholesterol, Aβ and Alzheimer's disease , 2001, Trends in Neurosciences.

[23]  M. Mercken,et al.  A Cholesterol-Lowering Drug Reduces β-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease , 2001, Neurobiology of Disease.

[24]  B. Hyman,et al.  Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid β-peptide , 2001, Nature Cell Biology.

[25]  Y. Ihara,et al.  Distinct Intramembrane Cleavage of the β-Amyloid Precursor Protein Family Resembling γ-Secretase-like Cleavage of Notch* , 2001, The Journal of Biological Chemistry.

[26]  C. Bergmann,et al.  Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  F. Bian,et al.  Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. , 2001, The American journal of pathology.

[28]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[29]  Robert V Farese,et al.  Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. , 2000, The Journal of biological chemistry.

[30]  A Cumano,et al.  A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. , 2000, Molecular cell.

[31]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[32]  F. Kuipers,et al.  Acyl‐coenzyme A: Cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7α‐hydroxylase in cultured rat hepatocytes and in vivo in the rat , 1999 .

[33]  D. Selkoe,et al.  Translating cell biology into therapeutic advances in Alzheimer's disease , 1999, Nature.

[34]  William J. Ray,et al.  A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain , 1999, Nature.

[35]  T. Saido.  Alzheimer’s Disease as Proteolytic Disorders: Anabolism and Catabolism of β-Amyloid , 1998, Neurobiology of Aging.

[36]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[37]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[38]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[39]  Allan I. Levey,et al.  Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.

[40]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[41]  R. Nicolosi,et al.  Pharmacological properties of a novel ACAT inhibitor (CP-113,818) in cholesterol-fed rats, hamsters, rabbits, and monkeys. , 1994, Journal of lipid research.

[42]  C. Masters,et al.  Rapid induction of Alzheimer A beta amyloid formation by zinc. , 1994, Science.

[43]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[44]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[45]  R. Tanzi,et al.  Amyloid β protein gene: cDNA, mRNA distribution and genetic linkage near the Alzheimer locus , 1988 .

[46]  P. S. St George-Hyslop,et al.  Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. , 1987, Science.

[47]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[48]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[49]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.

[50]  Laurent Chevreux,et al.  The Human Brain , 1979 .